Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%

NCT05659563 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

92

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Breast Cancer, Early-Onset

Interventions

DRUG: Giredestrant
DRUG: Tamoxifen

Sponsor

MedSIR